Financing channel feed – Endpoints News

Financing channel feed

A pharma exec gets $100M to chase a cancer-fighting idea uncovered in a 2017 Novartis study

5 years ago

Jeffrey Bluestone recruits a trio of biopharma vets to the startup team at Sonoma — while adding $30M to the launch round

5 years ago

Brent Saunders rides $400M wave to the top of the SPAC boom

5 years ago

Armed with a PhI cancer drug from Bayer, an Acerta founder breaks cover and writes himself a $60M blank check deal

5 years ago

MPM joins the historic SPAC boom as its blank check company files for an IPO

5 years ago

Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech

5 years ago

Aligos Therapeutics, developing several different hep B and NASH treatments, files for $100M IPO raise

5 years ago

InventisBio reels in $147M to push gout and breast cancer drugs along

5 years ago

Looking to conquer new territories, OrbiMed joins a $60M bet on a Biohaven spinout in Shanghai

5 years ago

SoftBank, Morningside help put US-China AI player on the map with $318M bet

5 years ago

Galecto reaps $64M to bring lead drug across IPF finish line, while making moves in NASH and beyond

5 years ago

The window is wide open as four more biotechs join the go-go IPO class of 2020

5 years ago

Palladio bags $20 million Series B to topple a problematic kidney disease drug

5 years ago

Following a hefty Series B, Silverback Therapeutics quickly pulls in $85M for 'an important growth phase'

5 years ago

Only five months after a Series A launch, Taysha goes public with $157M IPO

5 years ago

Monte Rosa rakes in $96M Series B as it prepares 'molecular glue' platform for IND-enabling studies

5 years ago

Flagship's next big technological bet? The cloud

5 years ago

With $29M in Series A, Boehringer-backed Libra looks to tackle neurodegeneration through cellular cleaning

5 years ago

As its biotechs hit the pandemic exit, Longitude raises $585M for new neuro, cancer, aging and orphan-focused fund

5 years ago

Immetas Therapeutics nabs $11M Series A to narrow their bispecific work targeting inflammation in age-related diseases

5 years ago

Zai Lab hauls in $761M from Hong Kong IPO to push Zejula, more budding candidates in China — report

5 years ago

Medicxi's David Grainger and Francesco De Rubertis pump €200M into six companies and what they say is a first-of-its kind fund

5 years ago

Israeli biotech raises $57M to go where current BRAF inhibitors can't, with backing from Novartis, SR One

5 years ago

Three more biotechs look to jump onto Nasdaq amid IPO boom, including Norbert Bischofberger's Kronos

5 years ago

First page Previous page 90 91 929394 95 96 Next page Last page